Tagged with Healthcare

Ecuador Angel Guevara, molecular biologist and professor at the Central University of Ecuador (UCE), discusses Ecuador’s potential as a clinical trial destination, a diverse tropical country with high prevalence of infectious disease and educated healthcare professionals. He explains the differences between public and private healthcare services, notably from the point of…

Lithuania Daina Klepone, managing director at Enterprise Lithuania, explains the opportunities Lithuania can offer to healthcare businesses and how their organization can help them enter the market. Moreover, she introduces the ‘Life Sciences Baltics’ event, and its key role to promote the industry in the Baltic region. Could you please start…

Serbia Serbia macroeconomic factsheet including data on population, GDP, education and life expectancy. Serbia has risen 50 places in the World Bank’s ‘Doing Business’ rankings from 93rd in 2014 to 43rd in 2018. Serbia’s GDP per capita between 2008 and 2016. International comparison of healthcare spending growth and GDP growth between…

Lithuania Vytautas Baublys, co-founder and CEO of Softneta, introduces the award-winning Lithuanian IT company, and its service offering, explaining how software-based specialized healthcare solutions improve the quality of patient care. Further, he discusses the importance of the company’s FDA-approved platform, facilitating the communication flow between scientists, doctors and patients, allowing them…

Serbia Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed treatments as well as an extremely challenging environment for innovative…

Lithuania Jūratė Sabalienė, who was appointed in September 2017 as the director of the National Health Insurance Fund (NHIF) of the Republic of Lithuania, explains her commitment as well as the back-up strategy to ensure the access to medicines of all Lithuanian patients in a financially sustainable manner. Could you please…

Lithuania Šarūnas Keserauskas, chairman of the Lithuanian Competition Council (KT), discusses his decision to return to Lithuania from the UK, EU collaboration, and the level of competition within Lithuania’s healthcare and life science industry. From the personal standpoint, after working nearly two years in the British National Competition Council, what triggered…

Lithuania Zydrune Visiockene, head of Vilnius University’s Center of Endocrinology and a key opinion leader on the topic of diabetes in the Baltics, casts his expert eye over the disease’s prevalence in Lithuania as well as the private and public sector initiatives currently underway to counter this important public health threat.…

Canada The government of the French-speaking Canadian province of Québec stands out for undertaking healthcare reforms while appreciating the need to join hands with industry when it comes to the promotion of health innovation. “Quebec has the most aggressive approach of any province in this country [for generics pricing]” Dr. Gaétan…

Serbia Suzana Djordjevic, director of the Hemofarm Foundation in Serbia, explores the themes of collectivism, social care and how individual acts can have profound outcomes in today’s world. Having enjoyed a colourful career working for NGOs, the media and the Serbian government, Suzana has always allowed her beliefs and passions to…

Brazil Armando Correa Lopes Jr, managing director of Siemens Healthineers Brazil, provides insights into the main trends and challenges at the core of Brazil’s healthcare discussion and documents the contribution of Siemens Healthineers in shaping a more cost-efficient, value-based, and data-oriented Brazilian model of healthcare. Leveraging your long-standing experience of Brazil’s…

Poland Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to…